Source: Eur Respir J 2015; 46: 570-573
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Vestjens Stefan M.T., Spoorenberg Simone M.C., Rijkers Ger T., Grutters Jan C., van de Garde Ewoudt M.W., Meijvis Sabine C.A., Bos Willem Jan W.. Antipyretic effect of dexamethasone in community-acquired pneumonia. Eur Respir J 2015; 46: 570-573

Member's Comments

No comment yet.

Related content which might interest you: Intravenous steroids in the treatment of community-acquired pneumonia (CAP) Source: Eur Respir J 2004; 24: Suppl. 48, 50s Year: 2004 Efficacy of corticosteroids in hospital treated community-acquired pneumonia Source: Annual Congress 2012 - Clinical management of lung diseases: from bronchi to pleura Year: 2012 Pathogen- and antibiotic-specific effects of prednisone in community-acquired pneumonia Source: Eur Respir J 2016; 48: 1150-1159 Year: 2016 Are corticosteroids useful in community-acquired pneumonia? Source: Annual Congress 2006 - Evaluation of risk factors in community-acquired pneumonia Year: 2006 Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia Source: Eur Respir J 2010; 36: 128-134 Year: 2010 Delirium induced by clarithromycin in a patient with community-acquired pneumonia Source: Eur Respir J 2006; 28: 671-672 Year: 2006 Ertapenem therapy for community-acquired pneumonia in the elderly Source: Eur Respir J 2005; 26: Suppl. 49, 638s Year: 2005 Oral antibiotics prior to hospitalisation for community-acquired pneumonia Source: Eur Respir J 2008; 31: 478-479 Year: 2008 Efficacy and safety of levofloxacin treatment of community-acquired pneumonia in hospitalized patients Source: Eur Respir J 2005; 26: Suppl. 49, 637s Year: 2005 Corticosteroids and community-acquired pneumonia Source: Annual Congress 2007 - Corticosteroids and respiratory failure Year: 2007 Nebulised colistin for ventilator-associated pneumonia prevention Source: Eur Respir J 2015; 46: 1732-1739 Year: 2015 Immunostimulating therapy in treatment of Community-acquired pneumonia Source: International Congress 2017 – CAP: severity scores, risk groups and biomarkers Year: 2017 Systemic corticosteroid for treating severe community-acquired pneumonia Source: International Congress 2015 – Advances in pneumonia management, COPD therapy and lung nodule evaluation Year: 2015 The approach to antibiotic treatment in community-acquired pneumonia Source: Annual Congress 2008 - MP14 - The approach to antibiotic treatment in community-acquired pneumonia Year: 2008 Low-dose corticosteroid use and mortality in severe community-acquired pneumonia patients Source: Eur Respir J 2015; 45: 463-472 Year: 2015 Atypical agents of community-acquired pneumonia (CAP) Source: Eur Respir J 2003; 22: Suppl. 45, 485s Year: 2003 Cost-effectiveness of full-course oral levofloxacin in severe community-acquired pneumonia Source: Eur Respir J 2004; 24 : 644-648 Year: 2004 Pharmacokinetic optimisation of β-lactams for the treatment of ventilator-associated pneumonia Source: Eur Respir Rev 2007; 16: 45-49 Year: 2007 Anti-Pseudomonas antibiotic use for hospitalized patients with community-acquired pneumonia Source: Virtual Congress 2020 – Lower respiratory tract infections in clinical practice Year: 2020